Document:

exv10w40

 

Exhibit 10.40

[ANADYS logo]

	 	 	 
	January 26, 2005

	 	VIA HAND DELIVERY

Jennifer K. Crittenden

[address]

[address]

Dear Ms. Crittenden:

I am very pleased to confirm the offer of employment made to you by Anadys Pharmaceuticals, Inc.
for the position of Vice President, Finance, initially reporting to Michael Kamdar, Senior Vice
President, Corporate Development and Finance. This position is exempt from state and federal
requirements regarding overtime payments, meaning you do not qualify for overtime. We anticipate
your hire date to be no later than February 22, 2005, however, the final date will be mutually
agreed upon. The details of this offer are as follows:

	 	 	 
	BASE SALARY:

	 	You will receive a base salary of $7,083.33 paid
semi-monthly in accordance with the normal Anadys
payroll cycle, which if annualized, amounts to
$170,000.00 per year.
	 
	 	 
	STOCK OPTIONS:

	 	Upon commencement of your employment with Anadys
and subject to the approval of the Board of
Directors, you will be eligible for an initial
stock option grant allowing you to purchase
30,000 shares of Anadys common stock at a fair
market value on the date of the grant. These
stock options are subject to the terms and
conditions outlined in the Anadys Equity
Incentive Plan. You will be provided full details
of the Anadys Equity Incentive Plan once you
begin employment.
	 
	 	 
	SIGN-ON BONUS:

	 	As a further incentive for you to join Anadys,
you will be given a one-time sign-on bonus of
$15,000, less applicable employment taxes. This
bonus will be paid to you over three quarters
after your hire date. Should you leave the
Company within one year of your hire date you
will be required to reimburse Anadys for this
sign-on bonus within thirty days after your
termination date. Should you receive a bonus in
excess of $5,000.00 from your current company,
you will be required to reimburse $5,000.00 to
Anadys.
	 
	 	 
	BONUS:

	 	You are eligible to receive an annual
discretionary bonus of between 0 — 20% of your
then current annual base salary, contingent upon
your own and the Company’s performance.
	 
	 	 
	BENEFITS:

	 	You will be eligible for group benefits for
yourself and your eligible dependents, effective
the first day of the month following your date of
hire, subject to the terms and conditions of the
relevant insurance plan. Basic benefits include
comprehensive health insurance; dental insurance,
and vision care insurance. In addition, you will
be eligible for term life insurance and long-term
disability insurance for yourself only. You will
be eligible to participate in the Anadys 401K
plan as well as the Anadys ESPP (Employee Stock
Purchase Plan), all in accordance with Company
policy. You will also receive 2 weeks of extra
paid vacation in addition to the regular accrued
pro-rata share of fifteen days of paid vacation
per year, and be eligible for paid holidays, all
in accordance with Company policy.

 

 

Jennifer Crittenden

January 17, 2005

	 	 	 
	EMPLOYMENT AT WILL:

	 	Anadys is an at-will employer and as such your
employment is to be entered into voluntarily and
for no specified period. As a result, you are
free to resign or the company may terminate your
employment at any time, for any reason, with or
without cause. No one other than the President
and CEO has the authority to alter this
employment relationship, either verbally or in
writing.

Anadys Pharmaceuticals, Inc. requires that you not disclose to it any proprietary information or
trade secrets of any former employer or bring onto its premises any unpublished documents or any
property belonging to any former employer.

This offer is subject to your signing non-disclosure and invention assignment agreements with the
Company, and the Company’s review of any agreement you may have with former employers to ensure
that they do not conflict with your employment with the Company. In addition, upon your date of
hire, you will be required to submit proof of identity and eligibility to work in the United
States, in compliance with federal immigration laws.

This offer has been extended to you on behalf of Anadys Pharmaceuticals, Inc. and is valid through
January 26, 2005, after which time it will expire. This offer includes all the terms of your
potential employment with the Company, and supersedes all prior and contemporaneous negotiations,
agreements and understandings between you and the Company, oral or written.

Jennifer, we believe you will be able to make an immediate contribution to Anadys’ effort, and
think you will enjoy the rewards of working for an innovative, fast-paced, energetic company. One
of the keys to our accomplishments is our outstanding people.

Sincerely yours,

ANADYS PHARMACEUTICALS, INC.

/s/ Mary Yaroshevsky-Glanville

Mary Yaroshevsky-Glanville

Senior Director, Human Capital

I hereby accept this offer of employment and accept the terms as stated above. I understand that as
an employee of Anadys, I will be expected to comply with all Company policies:

	 	 	 	 	 
	/s/ Jennifer K. Crittenden

	 	01/26/2005
	 	 
	 	 	 
	Jennifer K. Crittenden

	 	Date	 	 

2exv10w10

 

Exhibit 10.10

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

     THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into
effective as of February 27, 2006, by and between BioMed Realty Trust, Inc., a Maryland corporation
(the “REIT”), BioMed Realty, L.P., a Maryland limited partnership (the “Operating
Partnership” and, together with the REIT, the “Company”), and Matthew G. McDevitt (the
“Executive”).

     WHEREAS, the Company and the Executive desire to amend that certain Employment Agreement dated
as of August 6, 2004, between the Company and Executive (the “Original Agreement”), to
change Executive’s position with the Company.

     NOW, THEREFORE, in consideration of the various covenants and agreements hereinafter set
forth, the parties hereto agree as follows:

     1. Amendment to Section 2. Section 2(a)(i) of the Original Agreement is hereby
restated in its entirety to read as follows:

          “(i) During the Employment Period, the Executive shall serve as Regional Executive Vice
President of the REIT and the Operating Partnership and shall perform such employment duties as are
assigned by the REIT’s Chief Executive Officer and usual and customary for such positions. In such
position, the Executive shall report to the REIT’s Board of Directors or, if the Board of Directors
delegates such authority, to the REIT’s Chief Executive Officer. At the Company’s request, the
Executive shall serve the Company and/or its subsidiaries and affiliates in other offices and
capacities in addition to the foregoing. In the event that the Executive, during the Employment
Period, serves in any one or more of such additional capacities, the Executive’s compensation shall
not be increased beyond that specified in Section 2(b) of this Agreement. In addition, in the
event the Executive’s service in one or more of such additional capacities is terminated, the
Executive’s compensation, as specified in Section 2(b) of this Agreement, shall not be diminished
or reduced in any manner as a result of such termination for so long as the Executive otherwise
remains employed under the terms of this Agreement.”

     2. No Other Amendments. Except as expressly provided for in this Amendment, no other
term or provision of the Original Agreement is amended or modified in any respect.

(Signature Page Follows)

 

 

     IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first set forth
above.

	 	 	 	 	 
	 	BIOMED REALTY TRUST, INC.

 	 
	 	By:  	/s/ ALAN D. GOLD
 	 
	 	 	Name:  	Alan D. Gold 	 
	 	 	Title:  	Chief Executive Officer 	 
	 

	 	 	 	 	 	 	 
	 	 	BIOMED REALTY, L.P.
	 
	 	 	 	 	 	 
	 	 	By:	 	BioMed Realty Trust, Inc., its general partner
	 
	 	 	 	 	 	 
	 

	 	 	 	By: 
	/s/ ALAN D. GOLD	 
	 

	 	 	 	 	 	 
	 	 	 	 	Name: Alan D. Gold
	 	 	 	 	Title: Chief Executive Officer
	 
	 	 	 	 	 	 
	 	 	EXECUTIVE
	 
	 	 	 	 	 	 
	 	 	/s/ MATTHEW G. MCDEVITT	 	 
	 	 	 	 	 
	 	 	Matthew G. McDevitt	 

[SIGNATURE PAGE TO FIRST AMENDMENT TO EMPLOYMENT AGREEMENT]exv10w16

 

Exhibit 10.16

THIS WARRANT AND THE SECURITIES THAT MAY BE ACQUIRED UPON THE EXERCISE OF THIS WARRANT HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE
PROVISIONS OF ANY APPLICABLE STATE SECURITIES LAWS. NEITHER THIS WARRANT NOR THE SECURITIES THAT
MAY BE ACQUIRED UPON THE EXERCISE OF THIS WARRANT MAY BE SOLD, PLEDGED, TRANSFERRED, ASSIGNED OR
OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT AND APPLICABLE STATE SECURITIES LAWS OR UPON DELIVERY TO THE COMPANY OF AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE
SECURITIES LAW IS NOT REQUIRED.

STOCK PURCHASE WARRANT

VOID AFTER 5:00 P.M., EASTERN DAYLIGHT TIME

ON AUGUST 11, 2009

Date of Issuance: August 11, 2004                    Certificate No. W-1

     FOR VALUE RECEIVED, BioMed Realty Trust, Inc., a Maryland corporation (the “Company”), hereby
grants to Raymond James & Associates, Inc. or its registered assigns (the “Registered Holder”) the
right to purchase from the Company Two Hundred Seventy Thousand (270,000) shares of the Company’s
Common Stock, $0.01 par value per share (“Warrant Stock” or “Warrant Shares”) at a price per share
of $15.00 (as adjusted from time to time hereunder, the “Exercise Price”). Certain capitalized
terms used herein are defined in Section 6 hereof. The amount and kind of securities obtainable
pursuant to the rights granted hereunder and the purchase price for such securities are subject to
adjustment pursuant to the provisions contained in this Warrant.

     This Warrant is subject to the following provisions:

Section 1. Exercise of Warrant.

     1A. Exercise Period. The Registered Holder may exercise, in whole or in part, the
purchase rights represented by this Warrant at any time and from time to time after the Date of
Issuance to and including the date of the five (5) year anniversary of the effective date of the
public offering or private placement of the securities for which Raymond James & Associates, Inc.’s
services were utilized by the Company (the “Exercise Period”).

 

 

     1B. Exercise of Warrants

          (i) Method of Exercise. The Warrant evidenced hereby may be exercised by the
Registered Holder, in whole or in part, by the delivery at the principal office of the Company (or
at such other office or agency of the Company as it may designate by notice in writing to the
Registered Holder), during normal business hours, of this Warrant and the Exercise Agreement (in
the form attached hereto as Exhibit I), duly completed and executed, and payment of the Purchase
Price (as such term is defined in Section 1B(x) below) in cash, by wire transfer of immediately
available United States federal funds or by bank certified, treasurer’s or cashier’s check payable
to the order of the Company. Upon delivery of the Exercise Agreement, this Warrant and the
Purchase Price, the Company shall deliver to the Registered Holder that number of Warrant Shares
which is equal to the Purchase Price divided by the Exercise Price, as may be adjusted from time to
time.

          (ii) Cashless Exercise. In lieu of exercising the Warrant evidenced hereby pursuant
to Section 1B(i) above, the Registered Holder shall have the right during the Exercise Period to
exercise this Warrant, in whole or in part, by surrendering this Warrant to the Company accompanied
by the Form of Cashless Exercise (in the form attached hereto as Exhibit II), duly completed and
executed. Upon delivery of the Form of Cashless Exercise and this Warrant, the Company shall
deliver to the Registered Holder (without payment by the Registered Holder of any cash in respect
of the Purchase Price) that number of Warrant Shares which is equal to the amount obtained by
dividing (x) an amount equal to the difference between (1) the aggregate Market Price for the
Warrant Shares as to which the Cashless Exercise Right is then being exercised (the “Cashless
Exercise Shares”), determined as of immediately prior to the effective time of the exercise of the
Cashless Exercise Right, minus (2) the aggregate Exercise Price then applicable to the Cashless
Exercise Shares (such difference, the “Cashless Exercise Amount”), by (y) the Market Price of one
share of Common Stock determined as of the close of trading immediately prior to the effective time
of the exercise of the Cashless Exercise right. Upon exercise of the Cashless Exercise right, the
Cashless Exercise Amount shall be deemed to have been paid to the Company in respect of the Warrant
Shares so acquired. Any references in this Warrant to the “exercise” of this Warrant, and the use
of the term “exercise” herein, shall be deemed to include, without limitation, any exercise of the
Cashless Exercise right.

          (iii) Certificates for shares of Warrant Stock purchased upon exercise of this Warrant shall
be delivered by the Company to the Registered Holder as soon as practicable after surrender of the
Warrant and either (a) payment of the Purchase Price and delivery of the Exercise Agreement or (b)
delivery of the Form of Cashless Exercise

- 2 -

 

to the Company, and in any event within ten (10) business days after such surrender, payment and
delivery to the Company in the manner described above. Unless this Warrant has expired or all of
the purchase rights represented hereby have been exercised, the Company shall prepare a new
Warrant, substantially identical hereto, in the name of Registered Holder, representing the rights
formerly represented by this Warrant which have not expired or been exercised and shall, as soon as
practicable, deliver such new Warrant to the Registered Holder or to such Person as the Registered
Holder has designated for delivery.

          (iv) The Warrant Stock issuable upon the exercise of this Warrant shall be deemed to have been
issued to the Registered Holder as of the close of business on the date on which this Warrant shall
have been surrendered to the Company and delivery of (1) the Purchase Price and Exercise Agreement
or (2) Form of Cashless Exercise has been made to the Company, and the Registered Holder shall be
deemed for all purposes to have become the record holder of such Warrant Stock on that date.

          (v) The issuance of certificates for shares of Warrant Stock upon exercise of this Warrant
shall be made without charge to the Registered Holder with respect to any issuance tax or other
cost incurred by the Company in connection with such exercise and the related issuance of shares of
Warrant Stock provided, however, that the Company shall not be required to pay any tax which may be
payable in respect of any transfer involved in the issuance and delivery of any certificates in a
name other than that of the then Registered Holder of the Warrant being exercised. Each share of
Warrant Stock issuable upon exercise of this Warrant shall, upon payment of the Exercise Price, be
duly authorized, validly issued, fully paid and nonassessable and free from all liens and charges
with respect to the issuance thereof.

          (vi) The Company shall not close its books against the transfer of this Warrant or of any
share of Warrant Stock issued or issuable upon the exercise of this Warrant in any manner which
interferes with the timely exercise of this Warrant in accordance with its terms. The Company
shall from time to time take all such action as may be necessary to insure that the par value per
share of the unissued Warrant Stock acquirable upon exercise of this Warrant is at all times equal
to or less than the Exercise Price then in effect.

          (vii) The Company shall assist and cooperate with any Registered Holder required to make any
governmental filings or obtain any governmental approvals prior to, or in connection with, the
exercise of this Warrant, at the Registered Holder’s expense.

          (viii) The Company shall at all times reserve and keep available out of its authorized but
unissued shares of Warrant Stock, solely for the purpose of issuance upon the exercise of the
Warrants, at least such number of shares of Warrant Stock issuable upon the exercise in full of all
outstanding Warrants. The Company shall take all such actions as may be necessary to insure that
all such shares of Warrant Stock may be so issued without violation of any applicable law or
governmental regulation or any

- 3 -

 

requirements of any domestic securities exchange upon which shares of Warrant Stock may be listed
(except for official notice of issuance which shall be promptly delivered by the Company upon each
such issuance). The Company shall not take any action which would cause the number of authorized
but unissued shares of Warrant Stock to be less than the number of such shares required to be
reserved hereunder for issuance upon exercise of the Warrants.

          (ix) If the shares of Warrant Stock issuable by reason of exercise of this Warrant are
convertible into or exchangeable for any other stock or securities of the Company, the Company
shall, at the Registered Holder’s option and upon surrender of this Warrant by such holder as
provided above, together with any notice, statement or payment required to effect such conversion
or exchange of Warrant Stock, deliver to such holder (or such other Person specified by such
holder) a certificate or certificates representing the stock or securities into which the shares of
Warrant Stock issuable by reason of such conversion are convertible or exchangeable, registered in
such name or names and in such denomination or denominations as such holder has specified.

          (x) Purchase Price. The Purchase Price shall be the amount equal to the product of the
Exercise Price multiplied by the number of shares of Warrant Stock being purchased upon such
exercise.

     1C. Fractional Shares. If a fractional share of Warrant Stock would be issuable upon
exercise of the rights represented by this Warrant, the Company shall, as soon as practicable after
the date of exercise, deliver to the Registered Holder a check payable to the Registered Holder, in
lieu of such fractional share, in an amount equal to the difference between (x) the Market Price of
such fractional share as of the close of trading immediately prior to the effective time of the
exercise and (y) the Exercise Price of such fractional share.

Section 2. Adjustment of Exercise Price and Number of Shares. In order to prevent
dilution of the rights granted under this Warrant, the Exercise Price shall be subject to
adjustment from time to time as provided in this Section 2, and the number of shares of Warrant
Stock obtainable upon exercise of this Warrant shall be subject to adjustment from time to time as
provided in this Section 2.

     2A. Adjustments of Number of Shares/Price. If the Company shall (i) declare a
dividend on the Common Stock in shares of its capital stock (whether shares of Common Stock or of
capital stock of any other class), (ii) split or subdivide its outstanding shares of Common Stock,
(iii) combine its outstanding shares of Common Stock into a smaller number of shares, or (iv) issue
by reclassification of its shares of Common Stock any shares of capital stock or other securities
of the Company, then, in each such event, the number of shares of Common Stock purchasable upon
exercise of this Warrant immediately prior to the record date or effective date thereof, shall be
adjusted so that the holder of this Warrant shall be entitled to receive, upon the exercise of this
Warrant, the aggregate number and kind of shares of Warrant Stock or other securities which it
would have owned or have been entitled to receive after the

- 4 -

 

occurrence of any of the events described above, had such Warrant been exercised immediately
prior to the occurrence of such event (or any record date or effective date with respect thereto).
Such adjustment shall be made successively whenever any of the events listed above shall occur. An
adjustment made pursuant to this Section 2A shall become effective immediately after the effective
date of the event retroactive to the record date, if any, for such event. Whenever the number of
shares of Warrant Stock purchasable upon the exercise of this Warrant is adjusted pursuant to this
Section 2A, the Exercise Price per share of Warrant Stock payable upon exercise of this Warrant
shall be adjusted by multiplying such Exercise Price immediately prior to such adjustment by a
fraction, the numerator of which shall be the number of shares of Warrant Stock purchasable upon
the exercise of this Warrant immediately prior to such adjustment, and the denominator of which
shall be the number of shares of Warrant Stock purchasable immediately after such adjustment.

     2B. Subdivision or Combination of Common Stock. If the Company at any time subdivides
(by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its
outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced and the number of shares of
Warrant Stock obtainable upon exercise of this Warrant shall be proportionately increased. If the
Company at any time combines (by reverse stock split or otherwise) one or more classes of its
outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect
immediately prior to such combination shall be proportionately increased and the number of shares
of Warrant Stock obtainable upon exercise of this Warrant shall be proportionately decreased.

     2C. Reorganization, Reclassification, Consolidation, Merger or Sale. Any
recapitalization, reorganization, reclassification, consolidation, merger, sale of all or
substantially all of the Company’s assets or other transaction, which in each case is effected in
such a way that the holders of Common Stock are entitled to receive (either directly or upon
subsequent liquidation) stock, securities or assets with respect to or in exchange for Common Stock
is referred to herein as an “Organic Change.” Prior to the consummation of any Organic Change, the
Company shall make appropriate provision to insure that each of the Registered Holders of the
Warrants shall thereafter have the right to acquire and receive, in lieu of or in addition to (as
the case may be) the shares of Warrant Stock immediately theretofore acquirable and receivable upon
the exercise of such holder’s Warrant, such shares of stock, securities or assets as may be issued
or payable with respect to or in exchange for the number of shares of Warrant Stock immediately
theretofore acquirable and receivable upon exercise of such holder’s Warrant had such Organic
Change not taken place. In any such case, the Company shall make appropriate provision with
respect to such holders’ rights and interests to insure that the provisions of this Section 2 and
Sections 1, 3 and 4 hereof shall thereafter be applicable to the Warrants. The Company shall not
effect any such consolidation, merger or sale, unless prior to the consummation thereof, the
successor entity (if other than the Company) resulting from consolidation or merger or the entity
purchasing such assets assumes by written instrument, the obligation to deliver to each such holder
such shares

- 5 -

 

of stock, securities or assets as, in accordance with the foregoing provisions, such holder may be
entitled to acquire.

     2D. Certain Events. If any event occurs of the type contemplated by the provisions of
this Section 2, but not expressly provided for by such provisions, then the Company’s Board of
Directors shall make an appropriate adjustment in the Exercise Price and the number of shares of
Warrant Stock obtainable upon exercise of this Warrant so as to protect the rights of the holders
of the Warrants; provided that no such adjustment shall increase the Exercise Price or decrease the
number of shares of Warrant Stock obtainable as otherwise determined pursuant to this Section 2.

     2E. Notices.

          (i) Immediately upon any adjustment of Exercise Price, the Company shall give written notice
thereof to the Registered Holder, setting forth in reasonable detail and certifying the calculation
of such adjustment.

          (ii) The Company shall give written notice to the Registered Holder at least twenty (20) days
prior to the date on which the Company closes its books or takes a record (x) with respect to any
dividend or distribution upon the Common Stock, (y) with respect to any pro rata subscription offer
to holders of Common Stock, or (z) for determining rights to vote with respect to any Organic
Change, dissolution or liquidation.

          (iii) The Company also shall give written notice to the Registered Holder at least twenty (20)
days prior to the date on which any Organic Change, dissolution or liquidation shall take place.

Section 3. Liquidating Dividends. If the Company declares or pays a dividend upon the
Common Stock that is payable otherwise than in cash out of earnings or earned surplus (determined
in accordance with generally accepted accounting principles, consistently applied) (except for a
stock dividend payable in shares of Common Stock) (a “Liquidating Dividend”), then the Company
shall pay to the Registered Holder of this Warrant at the time of payment thereof the Liquidating
Dividend which would have been paid to such Registered Holder on the Warrant Stock had this Warrant
been fully exercised immediately prior to the date on which a record is taken for such Liquidating
Dividend, or, if no record is taken, the date as of which the record holders of Common Stock
entitled to such dividends are to be determined.

Section 4. Purchase Rights. If at any time the Company grants, issues or sells any
Options, Convertible Securities or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of any class of Common Stock (the “Purchase Rights”), then the
Registered Holder of this Warrant shall be entitled to acquire, upon the terms applicable to such
Purchase Rights, the aggregate Purchase Rights which such holder could have acquired if such holder
had held the number of shares of Warrant Stock acquirable upon complete exercise of this Warrant
immediately before the date on which a record is taken for the grant, issuance or sale of such
Purchase Rights, or, if no

- 6 -

 

such record is taken, the date as of which the record holders of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights.

Section 5. Registration Rights.

     5A. Piggyback Registration Rights. If at any time within the Exercise Period, the
Company proposes to file a registration statement with respect to any class of security under the
Securities Act in a primary registration on behalf of the Company and/or in a secondary
registration on behalf of holders of such securities, other than a registration statement relating
to employee benefit plans or corporate reorganizations or other transactions covered by Rule 145
promulgated under the Securities Act, a registration on any registration form which does not permit
secondary sales or does not include substantially the same information as would be required to be
included in a registration statement covering the sale of the Registrable Securities, or a
registration statement related to the initial public offering of the Company’s securities, the
Company will give written notice as soon as practicable, but not later than twenty (20) days prior
to the proposed filing date of the registration statement, to the Registered Holder and each holder
of Warrant Shares (the “Warrant Shareholders”) at the address appearing on the records of the
Company of its intention to file such registration statement and will offer to include in such
registration statement, to the maximum extent possible, such number of Registrable Securities with
respect to which the Company has received written requests from Warrant Shareholders (each a
“Selling Holder” and collectively the “Selling Holders”) for inclusion therein within ten (10) days
after the receipt of notice from the Company. All registrations requested pursuant to this Section
5A are referred to herein as “Piggyback Registrations.” The rights to Piggyback Registrations
provided for in this Section 5 shall expire upon the expiration of the Exercise Period.

          (i) Priority on Registrations. If a Piggyback Registration involves an underwriting,
the Company shall so advise the Warrant Shareholders as a part of the written notice given pursuant
to Section 5A. In such event, the right of a Warrant Shareholder to participate in that Piggyback
Registration shall be conditioned upon such Warrant Shareholder’s participation in such
underwriting and the inclusion of all or any part of the shares of Registrable Securities specified
in such Warrant Shareholder’s notice in the underwriting to the extent provided herein. The
Warrant Shareholder shall enter into an underwriting agreement in customary form with the
representative of the underwriter or underwriters selected by the Company. If the underwriter(s)
for the offering being registered by the Company shall determine in good faith and advise the
Company in writing that in its/their opinion the number of Registrable Securities requested to be
included in such registration exceeds the number that can be sold in such offering without
adversely affecting the distribution of such securities by the Company, the Company will include in
such registration (A) first, the securities that the Company proposes to sell, if any, (B) second,
the securities with demand registration rights requesting such registration, if any, and (C) third,
to the extent possible, the Registrable Securities and any other securities with piggyback
registration rights requesting to be included therein, apportioned pro rata among the holders of
such securities.

- 7 -

 

     5B. Obligations of the Company. Subject to the other provisions of this Section 5,
whenever required hereunder to use its reasonable efforts to effect the registration of any Warrant
Stock, the Company shall, as promptly as possible:

          (i) Bear the expenses of any registration or qualification under Section 5A, including, but
not limited to, underwriting, legal, accounting and printing fees; provided, however, that in no
event shall the Company be obligated to pay any fees and disbursements of special counsel for
Registered Holder of Registrable Securities or any underwriting discounts or commissions payable by
the Registered Holder;

          (ii) Furnish to the Selling Holders, prior to filing a registration statement, copies of such
registration statement as proposed to be filed, and thereafter such number of copies of such
registration statement, each amendment and supplement thereto (in each case including all exhibits
thereto), the prospectus included in such registration statement (including each preliminary
prospectus) and such other documents as the Selling Holders may reasonably request in order to
facilitate the disposition of the Warrant Stock owned by the Selling Holders;

          (iii) Prepare and file with the Securities and Exchange Commission (the “SEC”) a registration
statement on the appropriate form with respect to such Warrant Stock and any other shares of
capital stock included in such registration and use its reasonable efforts to cause such
registration statement to become effective as soon as practicable after such filing and remain
effective: (x) in the case of an underwritten offering, for such period as is required by the
underwriter for such offering or (y) in the case of an offering not underwritten, until the Selling
Holders have informed the Company in writing that the distribution of their securities has been
completed, but in no event longer than 120 days plus any period during which the Selling Holders
are obligated to refrain from selling because the Company is required to amend or supplement the
prospectus;

          (iv) Prepare and file with the SEC such amendments and supplements (including post-effective
amendments and supplements) to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the provisions of the
Securities Act with respect to the disposition of all securities covered by such registration
statement;

          (v) Notify the Selling Holders if, at any time when a prospectus relating to such Warrant
Stock is required to be delivered under the Securities Act, any event shall have occurred as a
result of which the prospectus then in use with respect to such Warrant Stock contains an untrue
statement of a material fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading, and prepare and furnish to all sellers as promptly as possible, a reasonable number
of copies of a supplement to or an amendment of such prospectus so that as thereafter delivered to
the Selling Holders of the Warrant Stock, such prospectus will not contain an untrue statement of a
material fact or omit to state any material fact required to be stated therein

- 8 -

 

or necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading;

          (vi) Use its reasonable efforts to register or qualify the securities covered by such
registration statement under such other securities or Blue Sky laws of such jurisdictions as the
Selling Holders may reasonably request for the distribution of the securities covered by the
registration statement and do any and all other acts and things which may be reasonably necessary
or advisable to enable the Selling Holders to consummate the distribution in such jurisdictions of
the Warrant Stock owned by the Selling Holders;

          (vii) Promptly notify such Selling Holders and the managing underwriters, if any,
participating in the distribution pursuant to such registration statement of the following promptly
after learning of the same: (A) when such registration statement or any post-effective amendment or
supplement thereto becomes effective or is approved; (B) of the issuance by any competent authority
of any stop order suspending the effectiveness or qualification of such registration statement or
the prospectus then in use or the initiation or threat of any proceeding for that purpose; and (C)
of the suspension of the qualification of any Warrant Shares included in such registration
statement for sale in any jurisdiction;

          (viii) Use its reasonable efforts to comply with all applicable rules and regulations of the
SEC, and make available to its security holders, as soon as reasonably practicable, an earnings
statement covering a period of twelve (12) months, beginning within three (3) months after the
effective date of the registration statement, which earnings statement shall satisfy the provisions
of Section 11(a) of the Securities Act and Rule 158 thereunder;

          (ix) Make available for inspection by each Selling Holder, and the underwriters, if any, of
such Warrant Shares and their respective counsel, accountants or agents, such access to its books
and records and such opportunities to discuss the business of the Company with its officers and
independent public accountants as shall be necessary to enable them to conduct a reasonable
investigation within the meaning of the Securities Act;

          (x) Enter into customary agreements (including an underwriting agreement in customary form, in
the case of an underwritten offering) and take such other actions as are reasonably required in
order to expedite or facilitate the disposition of such Warrant Shares;

          (xiii) In the event such sale is pursuant to an underwritten offering, use its reasonable
efforts to obtain a “cold comfort” letter from the Company’s independent public accountants in
customary form and covering such matters of the type customarily covered by “cold comfort” letters
as the Selling Holders or the underwriter reasonably request;

          (xi) Cooperate with the Selling Holders, the underwriter or underwriters (or broker/dealer
involved in the distribution), if any, and its respective counsel in

- 9 -

 

connection with any filings required to be made with the National Association of Securities Dealers
(the “NASD”);

          (x) Register the Warrant Shares for trading on the New York Stock Exchange or such other
exchange or trading market as the Common Stock is then listed;

     The Registered Holder agrees that, upon receipt of any notice from the Company (as to the
shares of Common Stock) of the happening of any event of the kind described in clause (vii) of
Section 5B, the Registered Holder will forthwith discontinue disposition of such shares pursuant to
the registration statement covering such Warrant Shares until the Registered Holder’s receipt of
the copies of the supplemented or amended prospectus contemplated by clause (vii) of this Section
5B, and, if so directed by the Company, the Registered Holder will deliver to the Company (at the
Company’s expense) all copies, other than permanent file copies then in the Registered Holder’s
possession of the prospectus covering such Warrant Shares then in the Registered Holder’s
possession current at the time of receipt of such notice. In the event the Company shall give any
such notice, the Company shall extend the period during which such registration statement shall be
maintained effective pursuant to this Warrant by the number of days during the period from and
including the date of the giving of such notice pursuant to clause (vii) of Section 5B to and
including the date when the Registered Holder shall have received the copies of the supplemented or
amended prospectus contemplated by clause (vii) of this Section 5B.

     5C. For purposes of this Section 5, the term, “Registrable Securities” shall mean the shares
issuable or issued upon exercise of the Warrant regardless of whether such Warrant has been
exercised. Nothing in this Section 5, however, shall be deemed to require the Company to register
the Warrant, it being understood that the registration rights granted hereby relate only to the
shares issuable or issued upon exercise of the Warrant and any securities issued in substitution or
exchange.

     5D. Indemnification. In the event any Warrant Stock is included in a registration statement
filed by the Company:

          (i) At the request of the Registered Holder in connection with a request for
registration made under Section 5, the Company agrees to execute and deliver a separate agreement
in customary form providing rights of contribution and indemnification, to the full extent
permitted by law, in favor of Registered Holder, its respective officers, directors and agents and
each person who controls the Registered Holder (within the meaning of the Securities Act), and any
investment adviser thereof or agent therefor (including brokers or dealers), against all losses,
claims, damages, liabilities and expenses caused by an untrue or alleged untrue statement of a
material fact contained in any registration statement, prospectus or preliminary prospectus or any
omission or alleged omission to state therein a material fact required to be stated therein (in the
case of a prospectus, in light of the circumstances under which they were made) not misleading,
except insofar as the same are made in reliance upon and conformity with any written information
with respect to the Registered Holder furnished to the Company by the Registered Holder expressly
for use therein or by the Registered Holder’s failure to deliver a copy of the registration
statement or prospectus or any

- 10 -

 

amendments or supplements thereto after the Company has furnished the Registered Holder with a
sufficient number of copies of the same. The Company will also indemnify any underwriters of
Warrant Stock, its officers, directors and agents and each person who controls such underwriters
(within the meaning of the Securities Act) to the same extent as provided above with respect to
indemnification of the Registered Holder; provided that, such indemnification shall not apply to
any untrue statement or omission made in reliance upon and in conformity with written information
furnished to the Company with respect to such underwriters by or on behalf of such underwriters
expressly for inclusion in the registration statement and the prospectus, or any amendment thereof
or supplement thereto.

          (ii) In connection with any registration statement in which the Registered Holder is
participating, the Registered Holder will furnish to the Company in writing such information with
respect to the Registered Holder as the Company reasonably requests for use in connection with any
such registration statement or prospectus and each such Registered Holder agrees to execute and
deliver a separate agreement in customary form providing indemnification, severally and not jointly
to the full extent permitted by law, in favor of the Company, its directors, officers, agents and
each person who controls the Company (within the meaning of the Securities Act) against any losses,
claims, damages, liabilities and expenses resulting by an untrue or alleged untrue statement
of a material fact contained in any registration statement, prospectus or preliminary prospectus or
any omission or alleged omission to state therein a material fact required to be stated
therein (in the case of a prospectus, in light of the circumstances under which they were
made) not misleading, to the extent, but only to the extent, that such untrue statement or omission
is contained in any information or affidavit with respect to such Registered Holder so furnished in
writing by such Registered Holder expressly for inclusion therein; provided,
however that such Registered Holder shall not be liable for any amounts exceeding the
proceeds for the sale of the Warrant Shares sold pursuant to said registration statement or
prospectus.

          (iii) The foregoing indemnity agreements of the Company and the Registered Holder are
subject to the condition that, insofar as they relate to any violation made in a preliminary
prospectus but eliminated or remedied in the amended prospectus on file with the SEC at the time
the registration statement in question becomes effective or the amended prospectus filed with the
SEC pursuant to Rule 424(b) of the Securities Act (the “Final Prospectus”), such indemnity
agreement shall not inure to the benefit of any Person if a copy of the Final Prospectus was
furnished to the indemnified party and was not furnished to the Person asserting such claim or loss
at or prior to the time such action is required by the Securities Act.

          5E. The Registered Holder shall not be entitled to exercise any right provided for in this
Section 5 after such time as Rule 144 or another similar exemption under the Securities Act is
available for the sale of all of the Registered Holder’s Warrant Shares during a three (3)-month
period without registration.

Section 6. Definitions. The following terms have meanings set forth below:

- 11 -

 

     “Common Stock” means, collectively, the Company’s Common Stock and any capital stock
of any class of the Company hereafter authorized which is not limited to a fixed sum or percentage
of par or stated value in respect to the rights of the holders thereof to participate in dividends
or in the distribution of assets upon any liquidation, dissolution or winding up of the Company.

     “Convertible Securities” means any stock or securities (directly or indirectly)
convertible into or exchangeable for Common Stock.

     “Market Price” means, on any date, the average of the daily closing prices for fifteen
(15) consecutive trading days commencing twenty (20) trading days before the date of such
computation. The closing price for each day shall be the average of the closing prices of such
security’s sales on all domestic securities exchanges on which such security may be listed at the
time, or, if there have been no sales on any such exchange on that day, the average of the highest
bid and lowest asked prices on all such exchanges at the end of such day, or, if on any day such
security is not so listed, the closing sale price of the Common Stock or, in case no sale is
publicly reported, the “Market Price” shall be the fair value thereof determined in good faith by
the Company’s Board of Directors.

     “Options” means any rights or options to subscribe for or purchase Common Stock or
Convertible Securities.

     “Person” means an individual, a partnership, a joint venture, a corporation, a limited
liability company, a trust, an unincorporated organization and a government or any department or
agency thereof.

     “Securities Act” means the Securities Act of 1933, as amended.

     “Warrant Stock” or “Warrant Shares” means the Company’s Common Stock; provided
that, if there is a change such that the securities issuable upon exercise of the Warrants are
issued by an entity other than the Company or there is a change in the type class of securities so
issuable, then the term “Warrant Stock” shall mean one share of the security issuable upon exercise
of the Warrants if such security is issuable in shares, or shall mean the smallest unit in which
such security is issuable if such security is not issuable in shares.

Section 7. Warrant Transferable. Subject to the transfer conditions referred to in the
legend endorsed hereon, this Warrant and all rights hereunder are transferable, in whole or in
part, without charge to the Registered Holder other than any applicable transfer taxes, upon
surrender of this Warrant with a properly executed Assignment (in the form of Exhibit III hereto)
at the principal office of the Company.

Section 8. NASD Matters. Notwithstanding anything to the contrary in this Warrant, the
Company agrees to modify any terms of the Warrant as reasonably requested by the Registered Holder
so as to enable the Registered Holder to comply with the Conduct

- 12 -

 

Rules of the NASD; provided that any such modification shall not adversely affect the Company or
its rights or obligations hereunder.

Section 9. Warrant Exchangeable for Different Denominations. This Warrant is
exchangeable, upon the surrender hereof by the Registered Holder at the principal office of the
Company, for new Warrants of like tenor representing in the aggregate the purchase rights
hereunder, and each of such new Warrants shall represent such portion of such rights as is
designated by the Registered Holder at the time of such surrender. The date the Company initially
issues this Warrant shall be deemed to be the “Date of Issuance” hereof regardless of the number of
times new certificates representing the unexpired and unexercised rights formerly represented by
this Warrant shall be issued. All Warrants representing portions of the rights hereunder are
referred herein as the “Warrants.”

Section 10. Replacement. Upon receipt of evidence reasonably satisfactory to the Company
(an affidavit of the Registered Holder shall be satisfactory) of the ownership and the loss, theft,
or destruction, or mutilation of any certificate evidencing this Warrant, and in the case of any
such loss, theft or destruction, upon receipt of indemnity reasonably satisfactory to the Company,
or, in the case of any such mutilation upon surrender of such certificate, the Company shall (at
the Registered Holder’s expense) execute and deliver in lieu of such certificate a new certificate
of like kind representing the same rights represented by such lost, stolen, destroyed or mutilated
certificate and dated the date of such lost, stolen, destroyed or mutilated certificate.

Section 11. Notices. Except as otherwise expressly provided herein, all notices referred
to in this Warrant shall be in writing and shall be delivered by registered or certified mail,
return receipt requested, postage prepaid or sent by reputable overnight courier service (charges
prepaid) and shall be deemed to have been given when so mailed or sent (1) to the Company, at its
principal executive offices and (2) to the Registered Holder of this Warrant, at such holder’s
address as it appears in the records of the Company (unless otherwise indicated by any such
holder).

Section 12. Descriptive Headings; Governing Law. The descriptive headings of the several
Sections and paragraphs of this Warrant are inserted for convenience only and do not constitute a
part of this Warrant. The corporation laws of the State of Maryland shall govern all issues
concerning the relative rights of the Company and its shareholders. All other questions concerning
the construction, validity, enforcement and interpretation of this Warrant shall be governed by the
internal law of the State of Maryland, without giving effect to any choice of law or conflict of
law provision or rule (whether of the State of Maryland or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of Maryland.

Section 13. Rights of Holder. The Registered Holder shall not, by virtue hereof, be
entitled to any rights of a shareholder of the Company, either at law or equity, and the rights of
the Registered Holder are limited to those expressed in this Warrant. Nothing contained in this
Warrant shall be construed as conferring upon the Registered Holder the

- 13 -

 

right to vote or to consent or to receive notice as a shareholder of the Company on any matters or
with respect to any rights whatsoever as a shareholder of the Company. No dividends or interest
shall be payable or accrued in respect of this Warrant or the interest represented hereby or the
Warrant Stock purchasable hereunder until, and only to the extent that, this Warrant shall have
been exercised in accordance with its terms.

Section 14. Representations and Covenants of Holder. This Warrant has been entered into
by the Company in reliance upon the following representations and covenants of the Registered
Holder, which by its execution hereof the Registered Holder hereby confirms:

Section 14A. Investment Purpose. This Warrant, and the Warrant Shares issuable upon
exercise hereof, are being acquired for investment and not with a view to the sale or distribution
of any part thereof, and the Registered Holder has not present intention of selling or engaging in
any public distribution of the same except pursuant to a registration or exemption.

Section 14B. Private Issue. The Registered Holder understands that (i) the Warrant Shares
issuable upon exercise of this Warrant are not registered under the Securities Act or qualified
under applicable state securities laws on the grounds that the issuance contemplated by this
Warrant will be exempt from the registration and qualification requirements thereof, and (ii) the
Company’s reliance on such exemption is predicated on the representations set forth in this Section
14.

Section 14C. Disposition of Holder’s Rights. In no event will the Registered Holder make
a disposition of any of its rights to acquire the Warrant Shares, or of any Warrant Shares issued
upon exercise of such rights, unless and until (i) it shall have notified the Company of the
proposed disposition and (ii) complied with the conditions referred to in the legend endorsed
hereon.

Section 14D. Financial Risk. The Registed Holder has such knowledge and experience in
financial and business matters as to be capable of evaluating the merits and risks of its
investment and has the ability to bear the economic risks of its investment.

Section 14E. Accredited Investor. The Registered Holder is an “accredited investor”
within the meaning of Rule 501 of Regulation D promulgated under the Securities Act.

- 14 -

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be signed and attested by its
duly authorized officers under its corporate seal and to be dated the Date of Issuance hereof.

BIOMED REALTY TRUST, INC.

	 	 	 	 
	By: 	/s/ ALAN D. GOLD
	 	 
	Name: Alan D. Gold	 
	Title: Chief Executive Officer
	 
	 
	 	 
	Attest:
	 	 

	 	 	 
	 
	 	 
	/s/ GARY A. KREITZER
	 	 
	 

Gary A. Kreitzer, Secretary

	 	 

- 15 -

 

EXHIBIT I

EXERCISE AGREEMENT

	 	 	 	 	 
	To:

	 	 
	 	Dated:

The undersigned, pursuant to the provisions set forth in the attached Warrant
(Certificate No. W-                    ), hereby irrevocably subscribes for the purchase of
                                        
shares of the Warrant Stock covered by such Warrant and makes payment
herewith in full at the price per share provided by such Warrant. The undersigned requests
that a certificate for such shares be issued in the name of [the undersigned] and be
delivered to [the undersigned] at the address stated below. The undersigned further
requests that, if the number of shares subscribed for herein shall not be all of the shares
purchasable hereunder, that a new Warrant of like tenor for the balance of the shares
purchasable hereunder be delivered to [the undersigned].

In exercising its rights to purchase the Warrant Stock, the undersigned hereby
confirms and acknowledges the investment representations and warranties made in Section 14
of the Warrant.

Signature                                                            

 

Address                                                            

- 16 -

 

EXHIBIT II

FORM OF CASHLESS EXERCISE

	 	 	 	 	 
	To:

	 	 
	 	Dated:

The undersigned hereby irrevocably elects a Cashless Exercise of the Warrant
represented by the attached Warrant (Certificate
No. W                    )
to purchase the shares of Common Stock issuable upon the exercise in accordance with Section 1B
(ii) of the Warrant and requests that certificates for such shares be issued in the
name of:

Please insert social security or other

identifying number

 

                                                                                

                                                                                

  

(Please print name and address)

 
                                                                                                                                                                

 
                                                                                                                                                                

If such number of Warrants shall not be all the Warrants evidenced by the Warrant,
a new Warrant for the balance remaining of such Warrant shall be registered in the
name of and delivered to:

Please insert social security or other

identifying number

 

                                                                                

                                                                                

  

(Please print name and address)

 
                                                                                                                                                                

 
                                                                                                                                                                

	 	 	 	 	 
	 
	 

	 	Dated:                                        ,                    
	 	                                                            
	 

	 	 	 	Signature
	 

	 	 	 	(Signature must conform in all
	 

	 	 	 	respects to name of holder as specified on
	 

	 	 	 	the face of this Warrant Certificate)

- 17 -

 

EXHIBIT III

FORM OF ASSIGNMENT

FOR
VALUE RECEIVED,                      hereby sells, assigns and transfers all of the rights of
the undersigned under the attached Warrant (Certificate
No. W-                    ) with respect
to the number of shares of the Warrant Stock covered thereby set forth below, unto:

	 	 	 	 	 
	Name of Assignee

	 	Address
	 	No. of Shares

	 	 	 	 	 	 	 
	Dated:

	 	Signature	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Witness	 	 	 	 
	 

	 	 	 	 

	 	 

- 18 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]